Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 Combination Therapy in HER2+ Gastroesophageal Adenocarcinoma
NCT06767800Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in gastroesophageal adenocarcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Nov 2024; status: recruiting.
02
Drugs
TQB2102
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT06767800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767800.